Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rony Dahan

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Cancer Cell|June 7, 2016
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR EngagementRony Dahan, Bryan C Barnhart, Fubin Li, et al.
Journal of Autoimmunity|October 5, 2013
Antigen-specific immunomodulation for type 1 diabetes by novel recombinant antibodies directed against diabetes-associates auto-reactive T cell epitopeRony Dahan, John A Gebe, Anton Preisinger, et al.
Nature Cancer|February 22, 2022
Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targetingRan Salomon, Hagar Rotem, Yonatan Katzenelenbogen, et al.
Science Immunology|March 3, 2023
Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacyNoy Cohen Saban, Adam Yalin, Tomer Landsberger, et al.
Nature Immunology|July 22, 2014
Type I and type II Fc receptors regulate innate and adaptive immunityAndrew Pincetic, Stylianos Bournazos, David J DiLillo, et al.
Nature Immunology|March 6, 2019
BCR affinity differentially regulates colonization of the subepithelial dome and infiltration into germinal centers within Peyer's patchesAdi Biram, Anneli Strömberg, Eitan Winter, et al.
Journal of Neuroscience Research|September 17, 2004
HLA-DRB1*1501 risk association in multiple sclerosis may not be related to presentation of myelin epitopesThomas P Finn, Richard E Jones, Cathleen Rich, et al.
Immunity|April 25, 2026
Pharmacologic glycoengineering of Fcγ receptor IIIa enhances force-resistant IgG-FcγR interactions and anti-tumor antibody efficacyBowie Yik-Ling Cheng, Raquel M Centeio, David Kung-Chun Chiu, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 16, 2007
A promising therapeutic approach for multiple sclerosis: recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNSSushmita Sinha, Sandhya Subramanian, Thomas M Proctor, et al.
European Journal of Immunology|April 7, 2011
TCR-like antibodies distinguish conformational and functional differences in two- versus four-domain auto reactive MHC class II-peptide complexesRony Dahan, Moran Tabul, Yuan K Chou, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Cancer Cell|June 7, 2016
Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR EngagementRony Dahan, Bryan C Barnhart, Fubin Li, et al.
Journal of Autoimmunity|October 5, 2013
Antigen-specific immunomodulation for type 1 diabetes by novel recombinant antibodies directed against diabetes-associates auto-reactive T cell epitopeRony Dahan, John A Gebe, Anton Preisinger, et al.
Nature Cancer|February 22, 2022
Bispecific antibodies increase the therapeutic window of CD40 agonists through selective dendritic cell targetingRan Salomon, Hagar Rotem, Yonatan Katzenelenbogen, et al.
Science Immunology|March 3, 2023
Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacyNoy Cohen Saban, Adam Yalin, Tomer Landsberger, et al.
Nature Immunology|July 22, 2014
Type I and type II Fc receptors regulate innate and adaptive immunityAndrew Pincetic, Stylianos Bournazos, David J DiLillo, et al.
Nature Immunology|March 6, 2019
BCR affinity differentially regulates colonization of the subepithelial dome and infiltration into germinal centers within Peyer's patchesAdi Biram, Anneli Strömberg, Eitan Winter, et al.
Journal of Neuroscience Research|September 17, 2004
HLA-DRB1*1501 risk association in multiple sclerosis may not be related to presentation of myelin epitopesThomas P Finn, Richard E Jones, Cathleen Rich, et al.
Immunity|April 25, 2026
Pharmacologic glycoengineering of Fcγ receptor IIIa enhances force-resistant IgG-FcγR interactions and anti-tumor antibody efficacyBowie Yik-Ling Cheng, Raquel M Centeio, David Kung-Chun Chiu, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 16, 2007
A promising therapeutic approach for multiple sclerosis: recombinant T-cell receptor ligands modulate experimental autoimmune encephalomyelitis by reducing interleukin-17 production and inhibiting migration of encephalitogenic cells into the CNSSushmita Sinha, Sandhya Subramanian, Thomas M Proctor, et al.
European Journal of Immunology|April 7, 2011
TCR-like antibodies distinguish conformational and functional differences in two- versus four-domain auto reactive MHC class II-peptide complexesRony Dahan, Moran Tabul, Yuan K Chou, et al.
Pageof 4